Indobufen crystal form E and preparation method thereof

Indobufen crystal form E prepared by specific heating and cooling treatment methods solves the problems of poor reproducibility and insufficient solubility of existing crystal forms, and achieves high purity, low hygroscopicity and good crystallinity, which is suitable for large Large-scale production and application of pharmaceutical preparations.

CN115872918BActive Publication Date: 2024-11-05HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111134156.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-09-27
Publication Date
2024-11-05
Estimated Expiration
2041-09-27

AI Technical Summary

Technical Problem

The existing indobufen crystal forms have poor reproducibility and cannot be prepared stably in large-scale production, and the solubility is insufficient to meet the needs of pharmaceutical preparations, especially in industrial production, the controllability and stability of the crystallization process are insufficient.

Method used

A new indobufen crystal form E was developed, which was prepared by specific heating and cooling treatment methods, with high purity, low hygroscopicity, good crystallinity and bulk morphology, and was spray-drying and rotary evaporation. Methods such as rapid precipitation simplify the preparation process to ensure the reproducibility and stability of the preparation.

Benefits of technology

The preparation method of crystal form E is simple, has high stability and good solubility, can maintain consistency in multiple batches, and is stable under high temperature, high humidity and light conditions. It is suitable for the development and storage of pharmaceutical preparations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention discloses an indobufen crystal form E, which is an anhydrous form. The solubility of the crystal form E in three biological media is FaSSIF>FeSSIF>FaSSGF from large to small. The crystal form E can stably exist in the three biological media without crystal transformation, and has good crystallinity, good thermal stability, poor hygroscopicity, a solvent-free preparation process, and is green and environmentally friendly.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of drug crystal forms, and particularly relates to an indobufen crystal form E and a preparation method thereof. Background Art

[0002] Thromboembolic disease is a type of systemic disease that affects the heart, brain and peripheral blood vessels. It is divided into arterial and venous types. High-risk patients for this type of disease include those with previous ischemic cerebrovascular disease, atrial fibrillation, long-term immobilization, intermittent claudication, etc. Prevention is more important than treatment, and antiplatelet drugs are widely used in preventing such thrombotic events.

[0003] Among various antiplatelet drugs, indobufen is an antithrombotic drug that effectively blocks platelet aggregation by reversibly inhibiting cyclooxygenase and reducing the production of thromboxane A2. It can selectively act on circulating platelets, block thrombus formation, inhibit the release of platelet factors and exert antiplatelet aggregation effects without changing plasma parameters or damaging platelet function, and can restore abnormal platelet function to normal.

[0004] In 2008, the American College of Chest Physicians (ACCP) guidelines proposed that indobufen is an effective platelet cyclooxygenase-1 (Cox-1) inhibitor, which is comparable to standard-dose aspirin in terms of both biochemical efficacy and clinical effectiveness. Compared with similar drugs, indobufen inhibits platelet factors, and its antiplatelet aggregation effect is 2 to 5 times that of salicylic acid, with a slightly shorter bleeding time. Compared with ticlopidine, there is no significant difference in oral clinical efficacy, but indobufen shows good tolerability.

[0005] Chinese invention patent CN106397298B discloses three crystalline forms of indobufen compounds, among which crystal form A is prepared by two methods: a) ultrasonic dissolution of indobufen and a solvent (selected from any proportion of ethanol / water, acetonitrile / water, 1,4-dioxane / water, ethyl acetate, butanone) and volatilization at room temperature to 60°C; b) ultrasonic dissolution of indobufen and a solvent (selected from any one of isopropanol, dimethyl sulfoxide, ethyl acetate) and diffusion in a water vapor atmosphere at room temperature to 40°C. The infrared spectrum of the crystal form has characteristic peaks at 2942, 1682, 1610, 1467, 1446, 1381, 1305, 1269, 1218, 1156, 959, 810 and 730 cm-1, and its dynamic adsorption curve shows that the weight change of the sample at 0% RH to 80% RH is about 0.06%.

[0006] Form B is prepared by heating indobufen to 189° C. at 10° C. / min and then cooling to 20° C. at 10° C. / min by DSC. The infrared spectrum of the crystal form has characteristic peaks at 2930, 1727, 1649, 1612, 1514, 1439, 1397, 1307, 1263, 1176, 929, 833 and 739 cm-1, and its dynamic adsorption curve shows that the weight change of the sample at 0% RH to 80% RH is about 0.14%.

[0007] Form C was obtained by ultrasonically dissolving indobufen and dichloromethane and then rapidly volatilizing under reduced pressure at 40°C. However, when the product was scaled up to 100 mg, Form B was obtained, indicating that Form C and its preparation process are unstable and cannot be scaled up for the time being.

[0008] The currently reported crystal forms and disclosed preparation methods are limited to the hundred milligram level. In order to meet the requirements of indobufen solid preparations for drug solubility, expand the raw material forms selected for preparation development, and at the same time meet the reproducibility and controllability of the crystallization process in the industrial production process, the art needs to develop new indobufen crystal forms and corresponding preparation methods suitable for industrial production. Summary of the invention

[0009] Among the existing reported crystal forms, the inventor of the present application repeated the preparation of crystal forms A and B according to the methods provided in Examples 9, 10, 13, and 14 of patent CN106397298B, and found that the reproducibility of crystal forms A and B was poor, and the corresponding crystal forms could not be obtained when the specification was 200 mg, and the solubility in the three biological media had no obvious advantage. Therefore, the present invention provides an indobufen crystal form E, which has a stable structure, a simple preparation method, is easy to scale up, and has improved crystal solubility.

[0010] The present invention provides an indobufen crystal form E, wherein the powder X-ray diffraction pattern of the crystal form E has a characteristic diffraction angle 2θ, a crystal plane spacing d and a relative intensity %, and a 2θ error of ±0.2 degrees; the X-ray powder diffraction pattern has diffraction peaks at least at one or more of 2θ angles of 6.346, 15.047, 22.976, 24.598, and 26.085.

[0011] Preferably, the characteristic diffraction angle 2θ includes 6.346, 13.479, 14.824, 15.047, 17.125, 20.060, 22.045, 22.976, 24.598, and 26.085.

[0012] More preferably, the crystalline form E has substantially the same Figure 1 The X-ray powder diffraction pattern shown has characteristic peaks and their relative intensities at the following diffraction angles 2θ:

[0013]

[0014]

[0015] As a further preferred embodiment, the TGA spectrum is shown in Figure 3 : Form E has only a 0.2±0.2% weight loss from room temperature to 100°C and decomposes at around 250°C.

[0016] As a further preference, the DSC spectrum is shown in Figure 3 : Crystalline Form E has obvious endothermic peaks at peaks of 167±2°C and 182±2°C, respectively. According to the results of thermal analysis, Crystalline Form E is anhydrous.

[0017] As a further preference, the DVS spectrum is shown in Figure 4 : Form E gained 0.10% weight at 95% RH and lost 0.04% weight at 0% RH, indicating that Form E had very poor hygroscopicity. XRPD results showed that the sample after DVS test did not undergo crystal form change.

[0018] Furthermore, the preparation method of the crystal form E of the present invention comprises the following steps:

[0019] The indobufen amorphous form is heated to 110-150° C. and then cooled to obtain Form E.

[0020] Further, preferably, the heating rate is 10-30°C / min; preferably, the heating process is to heat to 130°C.

[0021] Furthermore, preferably, the cooling is natural cooling.

[0022] Furthermore, preferably, the preparation method of the amorphous indobufen includes spray drying, rotary evaporation, rapid precipitation, thermal crystallization and the like.

[0023] As a specific embodiment, the method for preparing the amorphous indobufen is as follows: heating indobufen to 200-240° C., and then cooling to -5-5° C. to obtain the amorphous indobufen.

[0024] Further, preferably, the heating rate is 10-30°C / min; preferably, the temperature of the heating process rises to 230°C,

[0025] Furthermore, preferably, during the cooling process, the cooling rate is 20-50°C / min, down to 0°C.

[0026] The present invention also discloses a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and an effective amount of indobufen crystal form E.

[0027] Furthermore, the indobufen crystal form E is used in the preparation of a drug for preventing and / or treating antiplatelet diseases, wherein the disease is ischemic cardiovascular disease, ischemic cerebrovascular disease, venous thrombosis caused by arteriosclerosis, or for preventing thrombosis during hemodialysis.

[0028] Compared with the existing disclosed crystal forms, the advantages of the crystal forms described in the present invention are:

[0029] 1. By comparing the XRPD with the disclosed indobufen crystal forms, the crystal form E of the present invention has high purity (see the attached figure Figure 2 NMR), low hygroscopicity, good crystallinity and regular morphology.

[0030] 2. Form E can be prepared in multiple batches in small trials, indicating that the crystallization process has good reproducibility, stability and controllability; and the crystallization process is solvent-free and environmentally friendly.

[0031] 3. Crystal form E is a blocky crystal with good fluidity.

[0032] 4. The solubility test results show that the solubility of Form E in the three biological media is FaSSIF>FeSSIF>FaSSGF from high to low. Form E can exist stably in the three biological media without crystal transformation, which is of great significance for in vitro dissolution evaluation during the development of formulations.

[0033] 5. The solubility test results show that the solubility of Form E in the three biological media is better than that of the disclosed Forms A / B / I, and Form B undergoes crystal transformation during the test, while Form A undergoes melting crystal transformation at high temperature. Therefore, in terms of crystal stability, Form E is relatively stable among the currently disclosed crystals, and in terms of solubility in the three biological media, Form E is relatively superior among the currently disclosed crystals.

[0034] 6. Crystal form E has good stability under high temperature, high humidity and light conditions, and no crystal transformation occurs within 15 days, making it easy to store and transport for a long time. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 is the powder X-ray diffraction pattern of Form E;

[0036] Figure 2 : TGA spectrum and DSC spectrum of Form E;

[0037] Figure 3 is the DVS diagram of Form E;

[0038] Figure 4 is the powder X-ray diffraction pattern of Form E before and after DVS test;

[0039] Figure 5 is the PLM diagram of Form E;

[0040] Figure 6 The DSC diagrams at different stages in the preparation process of Form E in Example 2;

[0041] Figure 7 The DSC diagrams at different stages during the preparation of Form B in Example 4;

[0042] Figure 8 is the powder X-ray diffraction pattern of Form B in Example 4;

[0043] Fig. 9 This is the powder X-ray diffraction pattern of the stability study of Form E in Example 5;

[0044] Fig.10 The X-ray diffraction pattern of the powder of the solid remaining after the crystal form E in Example 6 was shaken in the medium for 24 hours. DETAILED DESCRIPTION

[0045] The present invention will be further described below with reference to the accompanying drawings and in combination with specific embodiments. The embodiments are provided to better illustrate the content of the present invention, but the content of the present invention is not limited to the embodiments. Therefore, those skilled in the art may make non-essential improvements and adjustments to the implementation scheme according to the above invention content, which still fall within the protection scope of the present invention.

[0046] Example

[0047] Testing instruments and methods:

[0048] 1. NMR analysis ( 1 H NMR)

[0049] Dissolve several milligrams of solid sample in dimethyl sulfoxide-d 6 NMR analysis was performed on a Bruker AVANCE-III (Bruker, GER) in solvent.

[0050] 2. X-ray powder diffraction (XRPD)

[0051] The solid samples obtained in the experiment were analyzed by X-ray powder diffractometer Bruker D8 Advance (Bruker, GER). The 2θ scanning angle was from 3° to 45°, the scanning step was 0.02°, and the exposure time was 0.12 seconds. When testing the samples, the tube voltage and current were 40 kV and 40 mA, respectively, and the sample pan was a zero background sample pan.

[0052] 3. Thermogravimetric analysis (TGA)

[0053] The model of the thermogravimetric analyzer is TA Discovery 55 (TA, US). 2-5 mg of sample was placed in a balanced open aluminum sample pan and automatically weighed in the TGA heating furnace. The sample was heated to the final temperature at a rate of 10 °C / min, and the nitrogen purge rate at the sample was 60 mL / min and the nitrogen purge rate at the balance was 40 mL / min.

[0054] 4. Differential Scanning Calorimetry (DSC)

[0055] The model of the differential scanning calorimeter was TA Discovery 2500 (TA, US). 1-2 mg of sample was accurately weighed and placed in a DSC Tzero sample pan with holes, and heated to the final temperature at a rate of 10°C / min, with a nitrogen purge rate of 50 mL / min in the furnace.

[0056] 5. Dynamic moisture adsorption and desorption analysis (DVS)

[0057] Dynamic moisture adsorption and desorption analysis was performed using DVS Intrinsic (SMS, UK). The test used a gradient mode, with humidity changes of 50%-95%-0%-50%, and the humidity change of each gradient in the range of 0% to 90% was 10%. The gradient endpoint was determined using the dm / dt method, with dm / dt less than 0.002% and maintained for 10 minutes as the gradient endpoint. After the test was completed, the sample was subjected to XRPD analysis to confirm whether the solid morphology had changed.

[0058] 6. Polarized light microscopy (PLM)

[0059] The polarizing microscope model is Nikon Ci-POL (Nikon, Japan). Place a small amount of sample on a glass slide and select a suitable lens to observe the sample morphology.

[0060] 7. High Performance Liquid Chromatography (HPLC)

[0061] The HPLC model was Waters Acquity Arc (Waters, US), and the test conditions were shown in Table 1.

[0062] Table 1 HPLC test conditions

[0063]

[0064] Example 1

[0065] Weigh indobufen sample (305.4 mg) and place it in a weighing bottle, heat it to 230°C in a blast drying oven, increase the temperature by 10°C / min, and keep the temperature constant until the sample is completely melted. Quickly take out the weighing bottle, place it at 0°C for 3 minutes, cool it down by 50°C / min, then place the weighing bottle in a 100°C blast drying oven, heat it to 130°C, increase the temperature by 10°C / min, keep the temperature constant for 10 minutes, and then cool it naturally to room temperature to obtain Form E, which is a solid with good crystallinity. Its powder X-ray diffraction pattern is shown in Figure 1 ;

[0066] TGA spectrum see Figure 2 : Form E has only 0.2% weight loss from room temperature to 100°C and may decompose at temperatures above 250°C.

[0067] DSC spectrum see Figure 2 : Form E has a melting endothermic peak at 167°C, followed by an exothermic signal corresponding to recrystallization at 171°C, and then a melting endothermic peak of the recrystallized solid appears at 182°C. According to the thermal analysis results, Form E is anhydrous.

[0068] DVS spectrum see Figure 3 : Form E gained 0.10% weight at 95% RH and lost 0.04% weight at 0% RH, indicating that Form E has very poor hygroscopicity; XRPD results showed that no crystal transformation occurred during the test (see Figure Figure 4 ).

[0069] PLM diagram Figure 5 : PLM images show that Form E is blocky crystals, and the size is generally less than 10 μm.

[0070] Example 2

[0071] Weigh an indobufen sample (85.6 mg) and place it in a weighing bottle. Heat it to 200°C using DSC at a heating rate of 10°C / min and keep the temperature constant until the sample is completely melted. Then cool it to 0°C at a cooling rate of 50°C / min, then heat it to 125°C at a heating rate of 10°C / min and keep the temperature constant for 10 min. Then naturally cool it to room temperature to obtain Form E.

[0072] The crystal form E was subjected to a heating-cooling (50°C / min)-reheating treatment using a DSC analyzer (see Figure 2). Figure 6 ), there is no obvious heat flow signal during the cooling process from 50℃ / min to 0℃; during the heating process from 50℃ / min to 125℃, it undergoes a glass transition at around 44℃ and there is a recrystallization exothermic peak at around 100℃.

[0073] Example 3

[0074] Weigh an indobufen sample (95.3 mg) and place it in a weighing bottle. Heat it to 200°C on a hot plate at a heating rate of 10°C / min. Maintain the temperature until the sample is completely melted. Then cool it to 0°C at a cooling rate of 50°C / min. Then heat it to 125°C at a heating rate of 10°C / min. Maintain the temperature for 10 min. Then naturally cool it to room temperature to obtain Form E.

[0075] Example 4 - Comparative Example

[0076] Weigh an indobufen sample (77.3 mg) and place it in a weighing bottle. Heat it to 200°C on a hot plate at a heating rate of 10°C / min. Keep the temperature constant until the sample is completely melted. Then cool it to 0°C at a cooling rate of 10°C / min. Then heat it to 115°C at a heating rate of 10°C / min. Keep the temperature constant for 10 min. Then cool it naturally to room temperature. Most of the solid obtained is form B, containing a few diffraction peaks of other forms.

[0077] Example 5 - Stability Test

[0078] About 10 mg of sample was weighed and placed in a weighing bottle, and placed under high temperature (60°C), high humidity (25°C / 92.5% RH), light (25°C / 4500 Lux), and accelerated (40°C / 75% RH). Samples were taken for XRPD characterization at 7 days and 15 days. The results are shown in Table 2. XRPD results show (see Figure Fig. 9 ), Form E was stable under high temperature, high humidity, light and accelerated conditions for 15 days without any crystal transformation.

[0079] Table 2 Form E stability study results

[0080]

[0081] Example 6 - Solubility Test

[0082] Dynamic solubility determination was performed on Form E in three biological solvents (FaSSIF, FeSSIF and FaSSGF), FaSSIF (Fasted State Simulated Intestinal Fluid, simulating the intestinal fluid in the small intestine of humans in a hungry state before a meal), FeSSIF (Fed State Simulated Intestinal Fluid, simulating the intestinal fluid in the small intestine of humans in a full state after a meal), and FaSSGF (Fasted State Simulated Gastric Fluid, simulating the gastric fluid when the stomach is empty when humans are hungry). The test method is to add about 30 mg of the sample to 4.0 mL of the biological medium and shake it at a constant temperature of 37°C for 24 hours, take samples at 0.5h, 2h and 24h, filter the sampled solution with a 0.22μm water filter membrane, appropriately dilute some samples with higher concentrations with a diluent, measure the signal peak area of ​​the solution with HPLC, and finally calculate the concentration of the compound in the solution based on the peak area, the HPLC standard curve of the raw material and the dilution factor. In addition, the pH value of the supernatant after 24 h was tested, and the remaining solid was subjected to XRPD test. The specific results are shown in Table 3.

[0083] The results showed that the 24h solubility of Form E in the biological medium was FaSSIF>FeSSIF>FaSSGF, and all the remaining solids did not undergo crystal transformation (see Figure Fig.10 ). At the same time, compared with the disclosed crystal forms, the 24h solubility of the crystal form E in the three biological media has obvious advantages.

[0084] Table 3 Dynamic solubility test in biological media

[0085]

[0086] The configuration process of the biological medium is shown in Table 4.

[0087] Table 4 Preparation process of biological medium

[0088]

[0089]

Claims

1. An indobufen crystalline form E, characterized in that: The powder X-ray diffraction pattern of the crystal form E has a characteristic diffraction angle 2θ, crystal plane spacing d and relative intensity %, and a 2θ error of ±0.2 degrees; the X-ray powder diffraction pattern has diffraction peaks at least at 2θ angles of 6.346, 15.047, 22.976, 24.598, and 26.

085.

2. The indobufen crystalline form E according to claim 1, characterized in that: The powder X-ray diffraction pattern of the crystalline form E has a characteristic diffraction angle 2θ, a crystal plane spacing d and a relative intensity %, and a 2θ error of ±0.2 degrees; the characteristic diffraction angle 2θ includes 6.346, 13.479, 14.824, 15.047, 17.125, 20.060, 22.045, 22.976, 24.598, and 26.

085.

3. The crystalline form E according to claim 1, characterized in that: It has an XRPD pattern substantially the same as that of Figure 1 of the accompanying drawings of the specification.

4. A method for preparing the crystalline form E according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: Heat the indobufen amorphous phase to 110-150 ° C and then cooled to obtain Form E; the heating rate is 10-30 ° C / min, the heating process is to heat up to 130 ° C; the cooling is natural cooling; The preparation method of the amorphous indobufen is as follows: heating the indobufen to 200-240°C at a heating rate of 10-30°C / min, and then cooling to 0°C at a cooling rate of 20-50°C / min to obtain the amorphous indobufen.

5. The crystalline form E according to any one of claims 1 to 3, characterized in that: The crystal form E is at room temperature to 100 ° C has a weight loss of 0.2±0.2% at 250 ° It starts to decompose around C.

6. The crystalline form E according to any one of claims 1 to 3, characterized in that: The DSC spectrum of the crystal form E has peaks at 167±2 ° C. 182±2 ° There is an obvious endothermic peak at C.

7. A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and an effective amount of the indobufen crystalline form E according to any one of claims 1 to 3.

8. Use of the indobufen crystal form E according to any one of claims 1 to 3 in the preparation of a medicament for preventing and / or treating an antiplatelet disease, wherein the disease is ischemic cardiovascular disease, ischemic cerebrovascular disease, venous thrombosis caused by arteriosclerosis, or for preventing thrombosis during hemodialysis.